Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: Association with adiponectin

European Journal of Heart Failure

Volumn 12, Issue 11, 2010, Pages 1214-1222

  Watanabe, Shin ^a   Tamura, Toshihiro ^a   Ono, Koh ^a   Horiuchi, Hisanori ^a   Kimura, Takeshi ^a   Kita, Toru ^b   Furukawa, Yutaka ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Adiponectin; Cardiac metabolism; Heart failure; Insulin like growth factor I; Outcomes

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; PHOSPHODIESTERASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SPIRONOLACTONE; SULFONYLUREA;

AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; FATTY ACID METABOLISM; FEMALE; GLUCOSE METABOLISM; HEART DEATH; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADIPONECTIN; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 77958604010     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq166     Document Type: Article

References (34)

1. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129.
2. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997;33:243-257.
3. Davila-Roman VG, Vedala G, Herrero P, De las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271-277.
4. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995;95:619-627.
5. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998;83:516-522.
6. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, Abel ED Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002 109 629-639.
7. ′-AMP-activated protein kinase activity does not impair recovery of contractile function during reperfusion of ischemic hearts. Am J Physiol Heart Circ Physiol 2009;297:H313-H321.
8. Diez J. Insulin-like growth factor I in essential hypertension. Kidney Int 1999;55: 744-759.
9. Ferry RJ Jr, Cerri RW, Cohen P. Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res 1999;51:53-67. (Pubitemid 29261682)
10. Abe N, Matsunaga T, Kameda K, Tomita H, Fujiwara T, Ishizaka H, Hanada H, Fukui K, Fukuda I, Osanai T, Okumura K. Increased level of pericardial insulin-like growth factor-1 in patients with left ventricular dysfunction and advanced heart failure. J Am Coll Cardiol 2006;48:1387-1395.
11. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829-1837.
12. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 2009;160:25-31.
13. Al-Obaidi MK, Hon JK, Stubbs PJ, Barnes J, Amersey RA, Dahdal M, Laycock JF, Noble MI, Alaghband-Zadeh J. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J 2001;142:E10.
14. Andreassen M, Kistorp C, Raymond I, Hildebrandt P, Gustafsson F, Kristensen LO, Faber J. Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. Growth Horm IGF Res 2009;19:486-490.
15. Ishizaka Y, Yamamoto Y, Fukunaga T, Yokota N, Kida O, Kitamura K, Kangawa K, Minamino N, Matsuo H, Eto T. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis 1994;24:461-472.
16. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002;55:65-85.
17. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968;405:5-37.
18. Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. J Clin Endocrinol Metab 1996;81:3902-3908.
19. Delaughter MC, Taffet GE, Fiorotto ML, Entman ML, Schwartz RJ. Local insulinlike growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J 1999;13:1923-1929.
20. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93: 800-809.
21. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351: 1233-1237.
22. Imazio M, Bobbio M, Broglio F, Benso A, Podio V, Valetto MR, Bisi G, Ghigo E, Trevi GP. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. Eur J Heart Fail 2002;4:185-191.
23. Lund LH, Freda P, Williams JJ, LaManca JJ, LeJemtel TH, Mancini DM. Growth hormone resistance in severe heart failure resolves after cardiac transplantation. Eur J Heart Fail 2009;11:525-528.
24. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-516.
25. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762.
26. Tamura T, Furukawa Y, Taniguchi R, Sato Y, Ono K, Horiuchi H, Nakagawa Y, Kita T, Kimura T. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 2007;71:623-630.
27. Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P. Adiponec-tin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009;11:567-572.
28. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N, Shintani Y, Minamino T, Asakura M, Kishimoto I, Funahashi T, Tomoike H, Kitakaze M. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-2077.
29. Tanaka T, Tsutamoto T, Sakai H, Nishiyama K, Fujii M, Yamamoto T, Horie M. Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur J Heart Fail 2008;10:360-366.
30. Marleau S, Mulumba M, Lamontagne D, Ong H. Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardi-omyopathies. Cardiovasc Res 2006;69:26-35.
31. Lavie CJ, Mehra MR, Milani RV. Obesity and heart failure prognosis: paradox or reverse epidemiology? Eur Heart J 2005;26:5-7.
32. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053.
33. Elgin RG, Busby WH Jr., Clemmons DR. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 1987;84:3254-3258.
34. Franklin SL, Ferry RJ Jr, Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 2003;88:900-907.